| pubmed-article:17514743 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17514743 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17514743 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:17514743 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:17514743 | lifeskim:mentions | umls-concept:C0030896 | lld:lifeskim |
| pubmed-article:17514743 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:17514743 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:17514743 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:17514743 | pubmed:dateCreated | 2007-5-24 | lld:pubmed |
| pubmed-article:17514743 | pubmed:abstractText | The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients >or=70 years of age. | lld:pubmed |
| pubmed-article:17514743 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17514743 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17514743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17514743 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17514743 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17514743 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:ByrdJohn CJC | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:KayNeil ENE | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:ShanafeltTait... | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:GreverMichael... | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:GeyerSusan... | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:LeungNelsonN | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:ZentClive SCS | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:LinThomasT | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:BowenDeborahD | lld:pubmed |
| pubmed-article:17514743 | pubmed:author | pubmed-author:KabatBrianB | lld:pubmed |
| pubmed-article:17514743 | pubmed:copyrightInfo | (c) 2007 American Cancer Society. | lld:pubmed |
| pubmed-article:17514743 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17514743 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17514743 | pubmed:volume | 109 | lld:pubmed |
| pubmed-article:17514743 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17514743 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17514743 | pubmed:pagination | 2291-8 | lld:pubmed |
| pubmed-article:17514743 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:meshHeading | pubmed-meshheading:17514743... | lld:pubmed |
| pubmed-article:17514743 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17514743 | pubmed:articleTitle | Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. | lld:pubmed |
| pubmed-article:17514743 | pubmed:affiliation | Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. shanafelt.tait@mayo.edu | lld:pubmed |
| pubmed-article:17514743 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17514743 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17514743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17514743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17514743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17514743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17514743 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17514743 | lld:pubmed |
